> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# IDEXX CEO Jonathan Mazelsky Plans To Sell 25,140 Shares Worth $17.7 Million
- URL: https://www.bullished.co/idexx-ceo-jonathan-mazelsky-plans-to-sell-25-140-shares-worth-17-7-million-4c7fa41b/
- Published: 2026-11-04T21:46:40.000Z
- Updated: 2026-11-04T21:46:40.000Z
- Description: The planned sale of IDEXX stock follows a same-day option exercise, and the shares are down about 7% over 12 months as of Tuesday's close.
- Author: Matteo Parrino
- Tags: Insider Trades, IDXX, Industry: Healthcare

Jonathan Jay Mazelsky, president and CEO of [IDEXX Laboratories](https://www.bullished.co/tag/idxx/), plans to sell [25,140 shares](https://www.sec.gov/Archives/edgar/data/0001556270/000195004726010676/xsl144X01/primary%5Fdoc.xml?ref=bullished.co) with a stated aggregate market value of $17.7 million, according to a Form 144, the notice insiders file before a planned sale. IDEXX makes diagnostic products and services mainly for veterinary clinics, livestock, poultry and dairy producers, and water testing.

## Option exercise feeds the sale

The shares come from a stock option exercise, which the filing says was acquired from the issuer on 11/04/2026 and paid for in cash. The approximate sale date listed is also 11/04/2026.

Morgan Stanley Smith Barney LLC Executive Financial Services is the named broker. The filing lists Mazelsky as both an officer and a director of the company.

## Where the stock stands

IDXX closed at $672.04 on Tuesday, the session before the filing, and at $698.55 on Wednesday. The shares were down about 0.7% this year and about 7% over the past 12 months as of Tuesday's close, within a 52-week range of $500.61 to $769.98.

IDEXX's largest business is its Companion Animal Group, which sells in-clinic analyzers, rapid test kits, reference laboratory testing, and practice management and imaging software to veterinarians. It also runs water-testing and livestock, poultry and dairy segments, according to its annual report for the year ended December 31, 2025.

Whether the sale is carried out would show up in a later insider transaction filing.

### Sources

- [Form 144 — Jonathan Jay Mazelsky (IDXX)](https://www.sec.gov/Archives/edgar/data/0001556270/000195004726010676/xsl144X01/primary%5Fdoc.xml?ref=bullished.co) — SEC EDGAR

### More on IDEXX Laboratories

- [IDEXX CEO Calls $15 Cancer Screen 'One Of The Most Consequential Innovations' In Company History](https://www.bullished.co/idexx-ceo-calls-15-cancer-screen-one-of-the-most-consequential-innovations-in-company-6322bd54/)
- [IDEXX Stock Soars 17%, Adding $7.5 Billion, After Raising 2026 Revenue And Earnings Outlook](https://www.bullished.co/idexx-stock-soars-17-adding-7-5-billion-after-raising-2026-revenue-and-earnings-outlook-1fc34fd9/)
- [IDEXX Lifts 2026 Revenue And EPS Outlook After 10% Sales Growth, But Cuts Margin Guidance](https://www.bullished.co/idexx-lifts-2026-revenue-and-eps-outlook-after-10-sales-growth-but-cuts-margin-guidance-fc97c400/)

[All IDEXX Laboratories (IDXX) coverage →](https://www.bullished.co/tag/idxx/)